Ryan Lim

Alpha Insights: Portfolio Strategy - 30/10/2025

The global financial system is approaching a critical juncture, and preparation is key.

ANN Analysis: Ansell 2025 AGM and Trading Update

Event: Ansell 2025 AGM and Trading Update | Date: 2025-10-29 | Source: Ansell ASX Announcements Shares Surge 6% on AGM Trading Update and Guidance Lift Ansell Limited held its 2025 Annual General Meeting on 29 October 2025, where it provided a positive trading update for the first quarter of FY26, highlighting stronger

AHC Analysis: Q1 FY26 Trading Update

Event: Q1 FY26 Trading Update | Date: 2025-10-28 | Source: Austco Healthcare Investor Relations Q1 Revenue Jumps 51% on Robust Demand and Backlog Austco Healthcare released its Q1 FY26 trading update on 23 July 2025, reporting revenue of $23.2 million, a 51% increase year-on-year, driven by strong order conversion and integration

Short Update - 29/10/2025

CSL Analysis: CSL Shares Plunge on US Vaccination Decline and Cost-Cutting Plan

Event: CSL Shares Plunge on US Vaccination Decline and Cost-Cutting Plan | Date: 2025-10-28 | Source: CSL Investor Relations CSL Shares Drop 8% as US Flu Vaccination Slump Prompts $500M Cost Overhaul CSL Limited announced a significant restructuring initiative in response to declining US influenza vaccination rates, which have fallen 25% post-pandemic

CSL: Plasma Giant - Transformation or Overvaluation?

CSL trades at $220.29 vs fair value $136.28 (62% premium). Strong plasma oligopoly moat (7.7/10 quality) executing $500M transformation targeting 34% EBITDA margins by FY28. Revenue growth 5.6% CAGR, but current valuation appears to fully reflect optimistic scenarios with limited margin of safety.

WZR: Fintech Lending Platform - Operational Excellence, Capital Structure Mess

Technology-driven consumer lending platform with superior credit quality (807 vs peer 650-780) but faces fundamental capital structure challenges. Fair value $0.25 vs current $3.50 implies -93% return. Negative FCF requires perpetual dilution.

TTT: Cold Spray Pioneer - Burning Cash, Building Dreams

Titomic trades at 620% premium to A$0.038 fair value despite -232% EBITDA margins. High-growth defence tech with 5-7 year patent moat faces binary execution risk on facility scaling and Tier-1 conversions. Venture capital-style bet requiring 3-5 year horizon.

JCS: SaaS Turnaround Story - Switching Costs Can't Switch Off Losses

Challenging turnaround play with fair value -$0.022 vs current $0.050. Persistent losses, 5% churn, narrow moat. High risk, negative outlook.

HGH: Specialist Banking Transformation - Demographic Goldmine at Cyclical Trough

Heartland Group Holdings: Fair value $2.24 vs current $0.955 (+136% upside). Specialist banking transformation with reverse mortgage dominance, ADI deposit advantages, demographic tailwinds. Credit cycle recovery catalyst.

Heading into the weekend

CCR: Debt Collections Disruptor - AI-Powered Turnaround Trades at Steep Discount

Credit Clear trades at $0.27 vs fair value $0.45 (67% upside), recently profitable with 15.8% EBITDA margin, 95% Tier-1 retention, technology moat 5-7 years